HistoCyte – Lung Cancer controls

Gaining over 15,000 cases this 2024 and leading with the lowest survival rate for cancer types, lung cancer has been in the forefront of cancer cases in Australia. Biomarkers such ALK, ROS1, PD-L1, and BRAF are used in IHC and molecular laboratory techniques to identify specific types of lung cancer and guide targeted therapy.

Think Biocartis Idylla

WHEN TIME MATTERS. THINK BIOCARTIS IDYLLA*. YOUR BIOMARKER TEST RESULTS WITHIN 3 HOURS. The Idylla™ solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.

Biocartis – Breast Cancer Portfolio

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Biocartis is pleased to launch a new breast cancer portfolio: Idylla™ PIK3CA-AKT1 Mutation Assay, APIS Breast Cancer Subtyping Kit and APIS ESR1 Mutations Kit.

Biocartis Idylla™ GeneFusion Assay*

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC. Within 180 minutes and with less than 2 minutes hands-on time, the fully automated Idylla™ GeneFusion cartridge detects ALK, ROS1, RET, NTRK1/2/3 rearrangements and MET exon 14 skipping in a single cartridge using only 1-3* FFPE tissue sections.

ZytoVision FISH probe for ROS1 translocations

Products are for professional/laboratory use only.  For patients with advanced lung cancer, the expected median survival is approximately one year however treatment with targeted tyrosine kinase inhibitor (TKI) therapy can improve outcomes for patients who have certain molecular alterations that can be identified by molecular testing1.

HistoCyte ROS1 Analyte Controls

ROS1 is a receptor tyrosine kinase (RTK) encoded by the ROS1 gene. Genetic rearrangements can occur with many different partner genes.